Catherine Alix-Panabières, Visiting Professor at University of Hamburg, shared an update from Genomic Medicine Sweden, on LinkedIn, adding:
“Delighted to be part of this Conference organized in LUND! Anders Edsjö and the scientific committee
I will talk about ‘Liquid Biopsy: The Rise of a Medical Revolution'”
Quoting Genomic Medicine Sweden:
“How can we translate the rapidly growing potential of liquid biopsy into clinical benefit for patients with cancer?
This autumn, we are delighted to welcome leading international expertise in liquid biopsy to Sweden – with opportunities to meet and hear from some of the researchers at the forefront of the field.
Liquid biopsy has enormous potential to give us a more dynamic picture of a patient’s cancer over time. The key now is to translate the rapidly advancing research into robust clinical applications that can make a real difference for patients,
says Emma Tham, Adjunct Professor of Clinical Genetics at Karolinska Institutet and Senior Consultant at Karolinska University Hospital.
Liquid biopsy is one of the most rapidly evolving areas in precision oncology. By analysing tumour-derived material circulating in the blood, such as circulating tumour DNA (ctDNA), it can provide valuable insights into the molecular characteristics of cancer – through a simple blood sample.
Already today, liquid biopsy can help identify genetic alterations that may guide treatment decisions in certain cancer settings. Looking ahead, its potential is even broader – from monitoring treatment response and emerging resistance to detecting minimal residual disease and potentially identifying recurrence earlier.
8 October, Genomic Medicine Sweden National Conference, Lund
We are especially pleased to welcome internationally renowned liquid biopsy experts Professor Catherine Alix-Panabières and Professor Klaus Pantel.
They will share insights from their latest research and explore how liquid biopsy is transforming the way we detect, monitor and understand cancer – and what it will take to translate these advances into routine clinical care and real benefits for patients.
10–11 November, Nordic Liquid Biopsy Conference, Uppsala
If you cannot join us in Lund, there will be another opportunity to hear Professor Klaus Pantel, who will also speak at the Nordic Liquid Biopsy Conference in Uppsala.
We look forward to an inspiring autumn of discussions on how liquid biopsy can move from scientific promise to clinical impact for patients.
This also can be interesting:
Liquid Biopsy and ctDNA After Cancer Treatment: Can ctDNA Detect Cancer Recurrence Before Scans?
